respiratory

In Response to a Broader FDA Investigation, ByHeart Initiates a Voluntary Recall of Two Batches of Infant Formula

NEW YORK--(BUSINESS WIRE)--ByHeart, a next-generation baby nutrition company, announced today that, out of an abundance of caution, it has chosen…

2 weeks ago

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II…

3 weeks ago

Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results

Posts Positive Organic Growth and Adjusted EBITDA‎1 of 23.5% of Revenue CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quipt Home…

3 months ago

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report"…

4 months ago

Drger Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Respiratory Devices Innovation

Dräger recognized for pioneering innovations in respiratory care, delivering measurable improvements in patient outcomes, clinical efficiency, cost-effectiveness and critical care…

5 months ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

5 months ago